[Weiboxin] New Product Launch | GENFAST Series Fully Automated Nucleic Acid Testing Analysis System

The GENFAST system is a fully automated nucleic acid detection and analysis platform, representing a new platform built in the molecular diagnostics field under Weiboxin’s open-platform ecosystem model. Suitable for pet health screening scenarios, such as pet hospitals and veterinary clinics. 
 

This series of analyzers employs rotary bead-based nucleic acid extraction and rapid fluorescent quantitative PCR detection, coupled with a unique reagent kit design that ensures assay containment. The system features simple manual operation, a fully automated workflow, and a total assay time of less than 30 minutes, significantly reducing turnaround time. Its compact and flexible design makes it an ideal solution for on-site rapid nucleic acid testing needs.

For animal disease testing reagents, please choose the Weiboxin brand.

Be aware of Weiboxin Bio All products of!

Official consultation phone numbers: 020-82298089 / 135 3988 6748, Ms. Dai

Overseas Service Hotline (Mobile/WhatsApp/WeChat): +86 18902342201

Email: sara@viuick.com

Guangzhou Weiboxin Biotechnology Co., Ltd. is a provincial-level “Little Giant” high-tech enterprise specializing in the forward R&D, manufacturing, sales, and technical services of diagnostic reagents for infectious diseases. The company is also recognized as a “Contract-Honoring and Credit-Keeping Enterprise” by Guangdong Province and a “Provincial Intellectual Property Demonstration Unit.” It serves as an industry–university–research collaboration base for Guangdong Food and Drug Vocational College and holds a standing directorship on the Veterinary Diagnostic and Biological Products Committee of the Guangdong Society of Animal Husbandry and Veterinary Medicine. Furthermore, it has been designated as an innovative, high-potential enterprise by multiple research institutions, including the Entrepreneurship College of Jinan University in Guangdong Province, and has been awarded the titles of “Specialized, Refined, Distinctive, and Innovative” enterprise at both municipal and provincial levels. The company has received the “Most Investment-Valuable Enterprise” award and the annual title of “ASF and Swine Disease Testing Service Provider,” and has obtained the approval number for veterinary drug products from the Ministry of Agriculture and Rural Affairs. : Veterinary Drug Registration No. 191438923 (Fluorescent PCR Test Kit for African Swine Fever Virus) 、 Veterinary Drug Registration No. 191438213 (Porcine Reproductive and Respiratory Syndrome Virus ELISA Antibody Detection Kit) 、 Veterinary Drug Registration No. 191438875 (Classical Swine Fever Virus Blocking ELISA Antibody Detection Kit) and Veterinary Drug Registration No. 191438851 (Porcine Circovirus Type 2 ELISA Antibody Detection Kit) The company was awarded the Excellence Prize in the Growth Category of the Biopharmaceutical Industry at the 11th China Innovation and Entrepreneurship Competition, as well as the Provincial Second Prize in the Growth Category of the Nanotechnology Industry Technology Competition under the Science and Technology Innovation and Entrepreneurship Competition. In the National Finals of the Nanotechnology Industry Technology Innovation Special Competition of the China Innovation and Entrepreneurship Competition, it further secured the National Third Prize in the Growth Category. Additionally, the company has consecutively received the A-Level Tax Credit Honor Certificate, the Four-Star Trademark and Brand Certification, and the Two-Integration Management System Assessment Certificate each year. It has also obtained ISO 9001 International Quality Management System Certification, ISO 14001 International Environmental Management System Certification, and GMP Certification from the Ministry of Agriculture. Since its establishment, the company has been granted a total of 24 patents, including 5 invention patents, 15 utility model patents, and 4 design patents, along with more than ten trademark registrations.

The company boasts robust technical capabilities and a world-class team of professionals, including dozens of masters, doctors, and returnees who studied abroad, as well as numerous senior-title technical experts. Currently, the company’s primary focus is on the R&D of molecular diagnostic reagents. Its core R&D team has developed more than 600 products spanning molecular diagnostics and immunoassays, including public-health–oriented fluorescent PCR test kits, animal disease–control fluorescent PCR test kits, clinical and research-grade fluorescent quantitative PCR kits, and transgenic identification test kits (ZL2006). The company has established a nationwide distribution network covering over ten major cities, such as Beijing, Shanghai, Hangzhou, Nanjing, Wuhan, Xi’an, Yunnan, Chongqing, Chengdu, Guizhou, Lanzhou, Zhengzhou, Qingdao, Inner Mongolia, and Xinjiang. Moreover, its products are now exported to numerous overseas markets, including the United Arab Emirates, Oman, Egypt, Pakistan, Paraguay, Poland, Colombia, Kazakhstan, Mongolia, Bangladesh, Myanmar, Mexico, Nigeria, Saudi Arabia, Spain, Armenia, India, Indonesia, Vietnam, and Cambodia, providing high-quality products and services to customers worldwide.

Looking ahead, Weiboxin will remain steadfast in its commitment to continuously enhance product quality and service standards. Leveraging a rapid and efficient research platform and abundant biomedical resources, we will conduct extensive and in-depth R&D and scientific research in the biomedical field, thereby contributing to human health and advancing life sciences. Quality is our lifeline, and innovation is our soul; we will unwaveringly uphold this philosophy as we strive to become the premier supplier of rapid diagnostic reagents and instruments.